Published in Mem Inst Oswaldo Cruz on March 01, 2009
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis (2012) 2.13
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol (2010) 1.33
Toxoplasmosis. Handb Clin Neurol (2013) 1.11
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis (2011) 1.09
Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine (2010) 1.04
Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun (2010) 1.03
Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study. J Clin Microbiol (2013) 0.95
Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice. Hum Immunol (2011) 0.94
Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. Vaccine (2014) 0.94
Congenital toxoplasmosis--a report on the Danish neonatal screening programme 1999-2007. J Inherit Metab Dis (2010) 0.92
Evaluation of the new Elecsys Toxo IgG avidity assay for toxoplasmosis and new insights into the interpretation of avidity results. Clin Vaccine Immunol (2012) 0.90
A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans. PLoS One (2015) 0.89
Comparison of the Vidas system and two recent fully automated assays for diagnosis and follow-up of toxoplasmosis in pregnant women and newborns. Clin Vaccine Immunol (2013) 0.87
Performance of Polymerase Chain Reaction Analysis of the Amniotic Fluid of Pregnant Women for Diagnosis of Congenital Toxoplasmosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.87
Functional dissection of Toxoplasma gondii perforin-like protein 1 reveals a dual domain mode of membrane binding for cytolysis and parasite egress. J Biol Chem (2013) 0.86
Antiparasitic treatment suppresses production and avidity of Toxoplasma gondii-specific antibodies in a murine model of acute infection*. Eur J Microbiol Immunol (Bp) (2011) 0.84
Toxoplasmosis and pregnancy. Can Fam Physician (2014) 0.84
Is Toxoplasma Gondii Infection Related to Brain and Behavior Impairments in Humans? Evidence from a Population-Representative Birth Cohort. PLoS One (2016) 0.84
Analysis of structures and epitopes of surface antigen glycoproteins expressed in bradyzoites of Toxoplasma gondii. Biomed Res Int (2013) 0.83
Protective immune response in BALB/c mice induced by DNA vaccine of the ROP8 gene of Toxoplasma gondii. Am J Trop Med Hyg (2013) 0.82
Identification and real-time expression analysis of selected Toxoplasma gondii in-vivo induced antigens recognized by IgG and IgM in sera of acute toxoplasmosis patients. BMC Infect Dis (2013) 0.82
Non-synonymous single nucleotide polymorphisms in the P2X receptor genes: association with diseases, impact on receptor functions and potential use as diagnosis biomarkers. Int J Mol Sci (2014) 0.80
Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice. Parasit Vectors (2014) 0.80
Chorioretinal lesions in mothers of children with congenital toxoplasmosis in the National Collaborative Chicago-based, Congenital Toxoplasmosis Study. Sci Med (Porto Alegre) (2010) 0.79
Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1. PLoS One (2013) 0.79
"Blind periods" in screening for toxoplasmosis in pregnancy in Austria - a debate. BMC Infect Dis (2012) 0.78
Evaluation of a new protocol for retrospective diagnosis of congenital toxoplasmosis by use of Guthrie cards. J Clin Microbiol (2014) 0.77
Identification of functional modules of AKMT, a novel lysine methyltransferase regulating the motility of Toxoplasma gondii. Mol Biochem Parasitol (2013) 0.76
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight (2016) 0.76
Ciprofloxacin Derivatives Affect Parasite Cell Division and Increase the Survival of Mice Infected with Toxoplasma gondii. PLoS One (2015) 0.76
Management of toxoplasmic retinochoroiditis during pregnancy, postpartum period and lactation: clinical observations. Med Sci Monit (2015) 0.75
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants. Clin Infect Dis (2015) 0.75
Reply to Wallon and Peyron. Clin Infect Dis (2015) 0.75
Toxoplasmic encephalomyelitis: III. A new case of granulomatous encephalomyelitis due to a protozoon. Am J Pathol (1939) 7.25
Congenital toxoplasmosis. A prospective study of 378 pregnancies. N Engl J Med (1974) 4.45
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med (1994) 4.32
Termination of pregnancy for maternal toxoplasmosis. Lancet (1994) 3.59
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med (1988) 3.15
Results of 20-year follow-up of congenital toxoplasmosis. Lancet (1986) 3.00
Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr (1989) 2.98
Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet (1999) 2.97
Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med (1994) 2.94
Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis (2001) 2.86
Genotype of 86 Toxoplasma gondii isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. J Infect Dis (2002) 2.78
Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis (2008) 2.73
Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol (2005) 2.66
Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis (2006) 2.63
Ocular toxoplasmosis. Br J Ophthalmol (1973) 2.60
Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis (1994) 2.58
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Prenatal diagnosis of congenital toxoplasmosis. Lancet (1985) 2.43
An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol (1992) 2.41
Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet (2007) 2.37
New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother (1984) 2.32
Population biology of Toxoplasma gondii and its relevance to human infection: do different strains cause different disease? Curr Opin Microbiol (2002) 2.21
Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci U S A (2006) 2.17
A correlative immunologic, microbiologic and clinical approach to the diagnosis of acute and chronic infections in newborn infants. N Engl J Med (1967) 2.09
Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol (1999) 1.92
The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg (1979) 1.82
Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol (2001) 1.78
Biological and genetic characterisation of Toxoplasma gondii isolates from chickens (Gallus domesticus) from São Paulo, Brazil: unexpected findings. Int J Parasitol (2002) 1.74
Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med (1974) 1.69
Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics (1977) 1.66
Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Med (1974) 1.64
Growth of Toxoplasma gondii is inhibited by aryloxyphenoxypropionate herbicides targeting acetyl-CoA carboxylase. Proc Natl Acad Sci U S A (1999) 1.62
Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects. Clin Infect Dis (2007) 1.58
Severe toxoplasmosis caused by a Toxoplasma gondii strain with a new isoenzyme type acquired in French Guyana. J Clin Microbiol (1998) 1.55
Subclinical central nervous system disease of neonates: a prospective study of infants born with increased levels of IgM. J Pediatr (1969) 1.50
Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis (2008) 1.49
The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol (2002) 1.48
In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother (2008) 1.48
Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG (2003) 1.47
Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med (1979) 1.46
Microbial causes of mental retardation. The role of prenatal infections with cytomegalovirus, rubella virus, and toxoplasma. Lancet (1969) 1.44
[Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women]. Presse Med (1968) 1.43
Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr (2005) 1.39
HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol (1999) 1.39
In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother (1990) 1.38
Manifestations and management of ocular toxoplasmosis. Bull N Y Acad Med (1974) 1.38
[Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy]. Ann Pediatr (Paris) (1984) 1.36
Update on unethical use of placebos in randomised trials. Bioethics (2003) 1.35
Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol (2001) 1.35
Ocular involvement in toxoplasmosis. Br J Ophthalmol (1993) 1.34
Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics (2004) 1.34
Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One (2008) 1.32
Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol (1996) 1.31
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study. Int J Epidemiol (2000) 1.30
Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics (1995) 1.30
Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. Am J Obstet Gynecol (2004) 1.28
Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand J Infect Dis Suppl (1992) 1.28
Pathogenesis of toxoplasmic retinochoroiditis. Parasitol Today (1999) 1.24
Evaluation of the possibilities for preventing congenital toxoplasmosis. Am J Perinatol (1994) 1.22
Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother (1992) 1.19
Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect (2003) 1.19
Congenital and maternal toxoplasmosis. A review of 300 congenital cases. Dev Med Child Neurol (1962) 1.16
Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother (1992) 1.15
Congenital toxoplasmosis in the newborn. Arch Dis Child (1953) 1.13
Congenital toxoplasmosis simulating haemolytic disease of the newborn. J Obstet Gynaecol Br Emp (1956) 1.11
Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis (2008) 1.10
Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics (2006) 1.10
In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii. Antimicrob Agents Chemother (1994) 1.10
Congenital toxoplasmosis. The Toxoplasmosis Study Group. Semin Pediatr Neurol (1994) 1.10
Toxoplasmosis and mental retardation--report of a case-control study. Mem Inst Oswaldo Cruz (1994) 1.10
Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother (1998) 1.09
Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol (1975) 1.09
Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes Infect (2006) 1.09
Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology (2007) 1.09
Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis J (2008) 1.09
Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol (2005) 1.04
Toxoplasma gondii isolates of free-ranging chickens from Rio de Janeiro, Brazil: mouse mortality, genotype, and oocyst shedding by cats. J Parasitol (2003) 1.04
Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br J Ophthalmol (2006) 1.04
Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. Pediatr Infect Dis J (2006) 1.03
Toxoplasmosis in pregnancy. Lancet (1994) 1.03
Treatment of uveitis with pyrimethamine (daraprim). Br J Ophthalmol (1956) 1.02
Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child (2006) 1.01
[A homogeneous series of 210 cases of congenital toxoplasmosis in 0 to 11-month-old infants detected prospectively]. Ann Pediatr (Paris) (1984) 1.01
Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol (2001) 1.00
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Am J Ophthalmol (2003) 0.99
Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolaryngol Head Neck Surg (1992) 0.97
[Experimental toxoplasmosis in mice. Comparative activity of clindamycin, midecamycin, josamycin, spiramycin, pyrimethamine-sulfadoxine, and trimethoprim-sulfamethoxazole]. Ann Pediatr (Paris) (1984) 0.97
Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J Am Vet Med Assoc (1990) 0.97
Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol (2001) 0.96
A multihousehold study reveals a positive correlation between age, severity of ocular toxoplasmosis, and levels of glycoinositolphospholipid-specific immunoglobulin A. J Infect Dis (2004) 0.96
Long-term follow-up of patients with congenital ocular toxoplasmosis. N Engl J Med (1996) 0.95
Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol (2006) 0.95
Intellectual deficits in children born with subclinical congenital toxoplasmosis: a preliminary report. J Pediatr (1973) 0.95
Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology (1996) 0.94
Anti-toxoplasmosis drugs. Curr Opin Investig Drugs (2001) 0.94
In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther (1993) 0.93
Prematurity and severity are associated with Toxoplasma gondii alleles (NCCCTS, 1981-2009). Clin Infect Dis (2012) 2.13
Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America. Clin Infect Dis (2011) 1.87
Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol (2008) 1.30
Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol (2011) 1.28
Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model. PLoS Negl Trop Dis (2011) 1.09
Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol (2008) 1.00
Cataracts in congenital toxoplasmosis. J AAPOS (2007) 0.98
Spinal Cord Lesions in Congenital Toxoplasmosis Demonstrated with Neuroimaging, Including Their Successful Treatment in an Adult. J Neuroparasitology (2012) 0.75